AU2023215314A1 - Therapeutic use of fibroblasts to stimulate the immune system - Google Patents

Therapeutic use of fibroblasts to stimulate the immune system Download PDF

Info

Publication number
AU2023215314A1
AU2023215314A1 AU2023215314A AU2023215314A AU2023215314A1 AU 2023215314 A1 AU2023215314 A1 AU 2023215314A1 AU 2023215314 A AU2023215314 A AU 2023215314A AU 2023215314 A AU2023215314 A AU 2023215314A AU 2023215314 A1 AU2023215314 A1 AU 2023215314A1
Authority
AU
Australia
Prior art keywords
cells
activated
fibroblasts
fibroblast
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023215314A
Other languages
English (en)
Inventor
Hamid Khoja
Pete O'HEERON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fibrobiologics Inc
Original Assignee
Fibrobiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrobiologics Inc filed Critical Fibrobiologics Inc
Publication of AU2023215314A1 publication Critical patent/AU2023215314A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2023215314A 2022-02-02 2023-02-02 Therapeutic use of fibroblasts to stimulate the immune system Pending AU2023215314A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263305973P 2022-02-02 2022-02-02
US63/305,973 2022-02-02
US202263383499P 2022-11-13 2022-11-13
US63/383,499 2022-11-13
PCT/US2023/061809 WO2023150590A2 (en) 2022-02-02 2023-02-02 Therapeutic use of fibroblasts to stimulate the immune system

Publications (1)

Publication Number Publication Date
AU2023215314A1 true AU2023215314A1 (en) 2024-08-15

Family

ID=87553049

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023215314A Pending AU2023215314A1 (en) 2022-02-02 2023-02-02 Therapeutic use of fibroblasts to stimulate the immune system

Country Status (6)

Country Link
US (1) US20250090594A1 (cg-RX-API-DMAC7.html)
EP (1) EP4472644A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505589A (cg-RX-API-DMAC7.html)
AU (1) AU2023215314A1 (cg-RX-API-DMAC7.html)
CA (1) CA3261913A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023150590A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025264574A1 (en) * 2024-06-17 2025-12-26 Fibrobiologics, Inc. Injectable thymus organoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338953B1 (en) * 1996-09-11 2002-01-15 The General Hospital Corporation Expression of an exogenous gene in a mammalian cell by use of a non-mammalian DNA virus having an altered coat protein
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
US20100178700A1 (en) * 2007-05-03 2010-07-15 Australian Stem Cell Centre Ltd. Novel thymic cellular populations and uses thereof

Also Published As

Publication number Publication date
CA3261913A1 (en) 2023-08-10
WO2023150590A2 (en) 2023-08-10
WO2023150590A3 (en) 2023-09-07
JP2025505589A (ja) 2025-02-28
EP4472644A2 (en) 2024-12-11
EP4472644A4 (en) 2026-02-25
US20250090594A1 (en) 2025-03-20

Similar Documents

Publication Publication Date Title
US20240173354A1 (en) Methods of inhibiting aging and treating aging-related disorders
US12150963B2 (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
AU2001238695B2 (en) Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
TW202330910A (zh) T細胞的製造方法
JP2024516172A (ja) 間葉系前駆体又は幹細胞を使用する急性呼吸窮迫症候群(ards)を治療するための方法
EP4472644A2 (en) Therapeutic use of fibroblasts to stimulate the immune system
US20230059649A1 (en) Temperature-based transient delivery of zscan4 nucleic acids and proteins to cells and tissues
TW202421780A (zh) T細胞的製造方法
US20250161367A1 (en) Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen
WO2024102777A2 (en) Compositions and method for expansion of embryonic stem cells
EP2270137A1 (en) Method for producing cells having characteristic of hematopoietic stem cells/progenitor cells
EP4177344A1 (en) Novel transplantation cells having reduced immunogenicity
CN119464288B (zh) 一种环状rna、过表达载体、构建方法、检测引物和应用
JP2022513490A (ja) 遺伝子編集線維芽細胞の治療的使用
WO2015153880A2 (en) Modulation of hotair and adipogenesis
JP2020132592A (ja) 生体内でドパミン神経細胞を保護する方法
JP2018201499A (ja) 安全性と抗炎症作用を高めた間葉系幹細胞
US20110223138A1 (en) Mesenchymal stem cells that express increased amounts of anti-apoptotic proteins
WO2025061158A1 (zh) 一种表达mcl1的低免疫原性细胞及其制备方法
WO2024248141A1 (ja) T前駆細胞の製造方法
WO2025264574A1 (en) Injectable thymus organoids
WO2021151029A1 (en) Therapeutic exosomes and method of producing them
EP1918366A1 (en) Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof
HK1117193A (en) Pleuripotent stem cells generated from adipose tissue-derived stromal cells and uses thereof